Smoking cessation treatments and alcohol drinking

戒烟治疗和饮酒

• 批准号: 7033211
• 负责人: SHERRY ANN MCKEE
• 金额: $ 29.46万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-05 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7033211
• 关键词: adult human (21+); alcoholic beverage consumption; alcoholism /alcohol abuse; alcoholism /alcohol abuse chemotherapy; antidepressants; bupropion; clinical research; combination chemotherapy; comorbidity; craving; drug screening /evaluation; drug withdrawal; emotions; human subject; human therapy evaluation; inhalation drug administration; nicotine replacement; patient oriented research; psychopharmacology; smoking; smoking cessation; substance abuse related behavior; tobacco abuse; transdermal drug delivery

DESCRIPTION (provided by applicant): Given the substantial health risks associated with concurrent alcohol and tobacco use, there has been a growing effort to address smoking cessation in those experiencing alcohol problems. Non-dependent hazardous drinkers have high rates of concurrent smoking and represent 80% of those who experience alcohol-related problems. Little is known about how best to promote smoking cessation in this population of drinkers who are at increased risk for poor smoking cessation outcomes. Pharmacotherapies for smoking cessation may promote improved quit rates in hazardous drinking smokers by reducing alcohol reactivity and consumption, thereby attenuating the ability of alcohol to prompt smoking relapse. Support for this project comes from a study by our group where we examined whether transdermal nicotine replacement ( 0 mg, 21 mg) altered reactivity to a fixed low dose of alcohol and subsequent ad-libitum consumption in moderate to heavy drinkers. Results demonstrated that 21 mg nicotine patch, compared to 6 hours of nicotine deprivation (placebo patch), decreased reactivity to the priming drink and reduced subsequent ad-libitum consumption. Current clinical practice guidelines indicate that combined nicotine replacement therapy (e.g., patch +nasal spray) and bupropion are two of the most efficacious pharmacotherapies available for smoking cessation. However, there is no research to date that has examined the effect of these two smoking cessation treatments on alcohol reactivity and self-administration behavior. Using similar procedures to our completed R03 project, the primary aim of STUDY 1 will be to examine whether 21 mg patch + nicotine spray, compared to 21 mg patch + placebo spray, alters reactivity to alcohol (.03g/dl priming drink) and subsequent ad-libitum drinking in individuals who are non-depndent hazardous drinking smokers. Specifically we will examine the effect of combined nicotine replacement on 1) ad-libitum alcohol consumption and alcohol craving, 2) tobacco craving and nicotine withdrawal, and 3) subjective intoxication and mood. STUDY 2 will be of similar design and aims examining bupropion (SOOmg vs. Omg). This proposal will have important treatment implications for improving rates of smoking cessation in hazardous drinkers and will contribute to the understanding of alcohol-nicotine interactions.

描述（由申请人提供）：鉴于与同时酒精和烟草使用相关的很大的健康风险，在遇到酒精问题的人中，越来越多的努力解决了戒烟。非依赖的危险饮酒者的同时吸烟率很高，代表了遇到酒精有关的问题的80％。关于如何最好地促进这种饮酒者的戒烟，这些饮酒者的戒烟风险较差，鲜为予戒烟。戒烟的药物疗法可以通过降低酒精反应性和消费来促进危险饮酒者的戒烟率，从而衰减酒精促使吸烟复发的能力。对该项目的支持来自我们小组的一项研究，我们检查了透皮尼古丁的替代品（0 mg，21 mg）是否改变了对固定的低剂量酒精的反应性，并随后在中度至饮酒者中消耗了Ad-Libitum。结果表明，与6小时的尼古丁剥夺（安慰剂斑块）相比，21 mg尼古丁斑块，对启动饮料的反应性降低，随后的Ad-libitum消耗减少。 当前的临床实践指南表明，尼古丁替代疗法（例如，斑块 +鼻喷雾剂）和安非他酮是可用于戒烟的两种最有效的药物治疗。但是，迄今为止尚无研究检查这两种戒烟治疗对酒精反应性和自我管理行为的影响。使用与我们完成的R03项目相似的程序，研究1的主要目的是检查21 mg斑块 +尼古丁喷雾剂是否与21 mg斑块 +安慰剂喷雾剂相比，改变了对酒精的反应性（.03g/dl启动饮料），以及随后是非痛苦的危害危害危害的人的饮酒。具体而言，我们将研究尼古丁替代品对1）1）脂肪饮酒和渴望的影响，2）烟草渴望和戒断尼古丁的戒烟，以及3）主观的中毒和情绪。研究2将具有类似的设计，目标是检查安非他酮（SOOMG与OMG）。该提案将对提高危险饮酒者的戒烟率具有重要的治疗意义，并有助于理解酗酒 - 烟碱相互作用。